Commentary: controversies in NICE guidance on management of type 2 diabetes
- PMID: 18535075
- PMCID: PMC2413391
- DOI: 10.1136/bmj.39581.495069.AD
Commentary: controversies in NICE guidance on management of type 2 diabetes
Conflict of interest statement
Competing interests: Both authors have been advisers to, or have received grants from, all major insulin and oral agent companies in the UK.
Comment on
-
Management of type 2 diabetes: summary of updated NICE guidance.BMJ. 2008 Jun 7;336(7656):1306-8. doi: 10.1136/bmj.39560.442095.AD. BMJ. 2008. PMID: 18535074 Free PMC article. No abstract available.
References
-
- National Institute for Health and Clinical Excellence. The management of type 2 diabetes (update). (Clinical guideline 66.) London: NICE, 2008. www.nice.org.uk/CG66
-
- Nathan DM, Buse JB, Davidson MB, Heine, RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72. - PubMed
-
- National Heart, Lung and Blood Institute. For Safety, HNLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. 2008. http://public.nhlbi.nih.gov/newsroom/home/getpressrelease.aspx?id=2551
-
- Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New Engl J Med 2007;357:1716-30. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical